• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
MPWElizabeth Holmes

The Rise and Fall of Elizabeth Holmes

By
Dan Primack
Dan Primack
Down Arrow Button Icon
By
Dan Primack
Dan Primack
Down Arrow Button Icon
July 8, 2016, 12:42 PM ET

Companies rise and fall all the time in America, almost as a hallmark of capitalism. But perhaps none has ever completed that cycle with the dizzying speed of Theranos, a Silicon Valley company that had promised to revolutionize the $50 billion blood-testing industry.

Theranos was founded in 2003 by Elizabeth Holmes, a Stanford dropout who managed to raise hundreds of millions of dollars in private funding without anyone in the media catching on for the next decade. In 2013, The Wall Street Journal reported that Theranos had developed blood analysis machines that could “automate and miniaturize more than 1,000 laboratory tests” in a manner that would “require only microscopic blood volumes.” It also revealed that the company had struck up a partnership with Walgreens (WBA), which would launch a network of in-store blood collection clinics. The following summer, Fortune put Holmes on its cover, revealing that private investors had valued her company at more than $9 billion.

From that moment on, Holmes was a bonafide business celebrity. And she embraced it, giving countless interviews and appearing on stage at numerous conferences―often in a black turtleneck seemingly designed to evoke memories of Steve Jobs.

Then, just 16 months after the Fortune cover, it all began to collapse. The Wall Street Journal returned its attention to Theranos, reporting that the company wasn’t using its own blood analysis machines to do many of its tests, and that there were accuracy concerns over the tests that were done on its machines. That story sparked a series of articles in the WSJ and elsewhere—including an unprecedented mea culpa from Fortune—and regulatory actions that caused many in Silicon Valley to conclude that Theranos was expert at marketing but lousy at science. Executives began to leave. The board, initially heavy on ex-politicos like Henry Kissinger and George Schultz, was reworked. And then reworked again. Walgreens bailed.

Last November, Holmes addressed the scrutiny at Fortune’s Global Forum with Alan Murray, which you can see here:

Finally this week, Theranos announced that federal regulators had banned Holmes from owning or operating a medical laboratory for at least two years, and that Theranos could no longer continue operating its California lab. Holmes, who has been promising to finally reveal compelling, peer-reviewed science at a medical conference next month, pledged to rebuild the California lab “from the ground up” but it’s unclear how she will finance such an endeavor.

Save for a miracle, this business story seems to have reached its final chapter. See the rest of its chapters below for our comprehensive coverage:

Theranos CEO Elizabeth Holmes Banned From Operating a Lab

Congress Is Demanding Theranos Explain How It’s Going to Fix Itself

Walgreens Is Officially Cutting Ties With Theranos

Theranos CEO Elizabeth Holmes Did Not Just Lose $4.5 Billion

After the Theranos Mess, Can We Finally Quit Idolizing Entrepreneurs?

Walgreens Reportedly Struck Theranos Deal Without Verifying the Tech

Theranos Is Now Facing a Class Action Lawsuit Accusing It of Consumer Fraud

Theranos CEO Elizabeth Holmes Needs An Assist. Literally.

Theranos Has Thrown Out Two Years of Blood-Test Results

Theranos’s President and COO Is Leaving

Theranos Under Investigation by SEC and U.S. Attorney’s Office

Theranos Chief Elizabeth Holmes Is ‘Devastated’ Over Lab Deficiencies

Theranos Founder Elizabeth Holmes Is Facing a Ban by Regulators

Tesla and Theranos Are Pushing the Limits of Silicon Valley’s Hype Machine

Theranos Adds Startlingly Well-Qualified Medical Board

Theranos on the Ropes as Scathing Regulatory Report Is Made Public

Theranos Is Dealt Another Blow, With ‘Abnormal’ Results in New Lab Study

Clinton Campaign Distances Itself From Controversial Blood-Testing Startup Theranos

Chelsea Clinton Is Holding a Fundraiser With the Embattled Theranos CEO

Theranos May Have Run Blood Tests Despite Problems With Quality

Walgreens Is Reportedly Taking Steps to Dump Theranos

Theranos May Lose Its Biggest Blood-Testing Customer

Theranos Has Yet to Begin a Promised Validation Study

Walgreens Gives Theranos Another Drop of Bad News

Theranos Practices ‘Pose Immediate Jeopardy to Patient Safety,’ Government Says

Theranos Is Facing Yet Another Problem at One of Its Labs

How Theranos Technology Struggled to Meet Elizabeth Holmes’ Ambitions

Letter to the Editor: Theranos Responds

How Theranos Misled Me

A Theranos Deal With Safeway Stores May be Falling Apart

Theranos’ Elizabeth Holmes Says the Company Will “absolutely” Get FDA Approval

The Theranos Mess: A Timeline

Theranos Founder-CEO Elizabeth Holmes: Feminist Icon?

Theranos Restructures Board Amid Questions About Its Technology

Theranos May Be Seeking to Raise $200 Million in New Funding

Here’s What the FDA Found Inside Theranos’ Lab

Walgreens Halts Expansion of Theranos Centers

Five Things to Know About the Man Defending Theranos

Theranos CEO Hits Back in Blood Feud With Wall Street Journal

Another Tale of Theranos Patient Woe

Ex-Apple Exec Describes First-Hand Experience Using Theranos Technology

Are the Wall Street Journal’s Allegations About Theranos True?

Theranos Controversy Has Little to Do With ‘Unicorns’

Theranos’ Board: Plenty of Political Connections, Little Relevant Expertise

WSJ Report: Theranos Is Struggling With Its Blood Test Technology

Beyond Blood: Theranos’ Billionaire Founder Talks Growth

This CEO Is Out for Blood

Stay tuned to Fortune for continuing coverage of the Theranos drama.

About the Author
By Dan Primack
See full bioRight Arrow Button Icon

Latest in MPW

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in MPW

NewslettersMPW Daily
Can Sheryl Sandberg’s Lean In take on tradwives and the manosphere?
By Emma HinchliffeMarch 27, 2026
17 hours ago
MPWMost Powerful Women
Influencer Alix Earle turned her worst insecurity into her first brand. This is her plan to monetize her 14 million followers and make it last
By Emma HinchliffeMarch 26, 2026
2 days ago
MagazineCentene
The youngest-ever female CEO of a Fortune 500 company is fighting Trump’s cuts to keep Medicaid strong
By Diane BradyMarch 24, 2026
4 days ago
AsiaPepsiCo
Three Asias, three different playbooks: How PepsiCo’s Anne Tse views the world’s fastest-growing snack market
By Nicholas GordonMarch 20, 2026
7 days ago
NewslettersMPW Daily
Inside one CEO’s battle to get a tariff refund: ‘We did take a beat to consider the best path’
By Claire ZillmanMarch 18, 2026
10 days ago
NewslettersMPW Daily
Hinge is growing while online dating competitors are struggling. Its new CEO explains why
By Ellie AustinMarch 17, 2026
11 days ago

Most Popular

Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action by blocking his calendar every afternoon from Wednesday to Friday 
By Fortune EditorsMarch 27, 2026
23 hours ago
AI
Exclusive: Anthropic acknowledges testing new AI model representing ‘step change’ in capabilities, after accidental data leak reveals its existence
By Fortune EditorsMarch 26, 2026
1 day ago
Personal Finance
Current price of gold as of March 27, 2026
By Fortune EditorsMarch 27, 2026
19 hours ago
AI
Exclusive: Anthropic left details of an unreleased model, invite-only CEO retreat, sitting in an unsecured data trove in a significant security lapse
By Fortune EditorsMarch 26, 2026
1 day ago
Personal Finance
Current price of silver as of Friday, March 27, 2026
By Fortune EditorsMarch 27, 2026
20 hours ago
Commentary
The Treasury just declared the U.S. insolvent. The media missed it
By Fortune EditorsMarch 23, 2026
5 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.